Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 12.66
(0.48%)
HKD 12.66
(0.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.28 Billion CNY | -9.79% |
| 2022 | 3.64 Billion CNY | 8.48% |
| 2021 | 3.35 Billion CNY | 16.21% |
| 2020 | 2.89 Billion CNY | 95.48% |
| 2019 | 1.47 Billion CNY | 115.96% |
| 2018 | 684.79 Million CNY | 97.66% |
| 2017 | 346.44 Million CNY | 129.31% |
| 2016 | 151.08 Million CNY | 101.94% |
| 2015 | 74.81 Million CNY | 97.99% |
| 2014 | 37.78 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 625.22 Million CNY | 14.48% |
| 2024 Q1 | 591.28 Million CNY | -50.29% |
| 2023 FY | 3.28 Billion CNY | -9.79% |
| 2023 Q1 | 777.25 Million CNY | -58.62% |
| 2023 Q3 | -17.33 Million CNY | -102.31% |
| 2023 Q4 | 1.18 Billion CNY | 6960.51% |
| 2023 Q2 | 749.31 Million CNY | -3.59% |
| 2022 Q3 | 108.91 Million CNY | -86.04% |
| 2022 Q1 | 849.36 Million CNY | -22.23% |
| 2022 FY | 3.64 Billion CNY | 8.48% |
| 2022 Q4 | 1.87 Billion CNY | 1624.77% |
| 2022 Q2 | 780.25 Million CNY | -8.14% |
| 2021 Q3 | 735.95 Million CNY | 9.97% |
| 2021 Q4 | 1.09 Billion CNY | 48.4% |
| 2021 Q1 | 873.47 Million CNY | -9.01% |
| 2021 Q2 | 669.22 Million CNY | -23.38% |
| 2021 FY | 3.35 Billion CNY | 16.21% |
| 2020 Q2 | 699.67 Million CNY | 83.94% |
| 2020 FY | 2.89 Billion CNY | 95.48% |
| 2020 Q4 | 959.99 Million CNY | 14.1% |
| 2020 Q3 | 841.39 Million CNY | 20.26% |
| 2020 Q1 | 380.38 Million CNY | -25.9% |
| 2019 Q1 | 444.57 Million CNY | 54.4% |
| 2019 Q4 | 513.35 Million CNY | 43.58% |
| 2019 Q3 | 357.55 Million CNY | 142.73% |
| 2019 Q2 | 147.3 Million CNY | -66.87% |
| 2019 FY | 1.47 Billion CNY | 115.96% |
| 2018 Q1 | 102 Million CNY | 19.68% |
| 2018 Q3 | 157.31 Million CNY | -7.73% |
| 2018 FY | 684.79 Million CNY | 97.66% |
| 2018 Q2 | 170.49 Million CNY | 67.14% |
| 2018 Q4 | 287.93 Million CNY | 83.03% |
| 2017 FY | 346.44 Million CNY | 129.31% |
| 2017 Q3 | 81.13 Million CNY | 7.45% |
| 2017 Q4 | 85.23 Million CNY | 5.04% |
| 2017 Q2 | 75.51 Million CNY | -8.15% |
| 2017 Q1 | 82.21 Million CNY | 131.71% |
| 2016 FY | 151.08 Million CNY | 101.94% |
| 2016 Q1 | 24.2 Million CNY | -12.76% |
| 2016 Q4 | 35.48 Million CNY | -33.3% |
| 2016 Q3 | 53.19 Million CNY | 119.75% |
| 2016 Q2 | 24.2 Million CNY | -0.0% |
| 2015 Q4 | 27.74 Million CNY | 0.0% |
| 2015 Q2 | 9.66 Million CNY | -0.0% |
| 2015 Q1 | 9.66 Million CNY | -22.96% |
| 2015 FY | 74.81 Million CNY | 97.99% |
| 2015 Q3 | 27.74 Million CNY | 187.24% |
| 2014 Q3 | 12.53 Million CNY | 97.31% |
| 2014 FY | 37.78 Million CNY | 0.0% |
| 2014 Q2 | 6.35 Million CNY | -0.0% |
| 2014 Q1 | 6.35 Million CNY | 0.0% |
| 2014 Q4 | 12.53 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -911.314% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | -344.674% |